Combination chemotherapy in platinum-resistant ovarian cancer ... is supposed to change the therapeutic landscape not only in primary ovarian cancer therapy but also for recurrent disease.

platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. The company noted that ...

“It's been ten years since a new treatment for platinum-resistant ovarian cancer ... competitive advantage for AbbVie in the ovarian cancer treatment landscape. GlobalData is the parent company ...

platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere, which won initial U ...

This first FDA antibody-drug conjugate (ADC)-approval for platinum-resistant ovarian cancer indication covers those patients who have undergone one to three prior systemic treatment regimens ...

offered phase I data from the Mythic gynecologic expansion trial testing the combination of lunresertib and camonsertib at the recommended phase II dose in patients with endometrial cancer and ...

or resistant to treatment. Patients who have recurrent ovarian cancer—especially those whose disease is resistant to platinum-based chemotherapy, the standard-of-care treatment—currently have ...

Th e GINECO trial explored the combination of trastuzumab with paclitaxel and carboplatin in patients with resistant AOC ... [FISH] positive) ovarian cancer progressing under taxane/carboplatin ...